Diffuse large B cell lymphoma: Management of second or later relapse in medically-fit patients

This algorithm should be used with related UpToDate topics for diagnosis, staging, and management of relapsed or refractory DLBCL. Treatment of CNS involvement should be initiated prior to systemic therapy. Refer to related topic for selection of CAR-T cell, BiTE, and other antibody-based agents.

DLBCL: diffuse large B cell lymphoma; CAR-T cell: chimeric antigen receptor T cell; BiTE: bispecific T cell engager antibody; CNS: central nervous system; HCT: hematopoietic cell transplantation.

* If CAR-T cell therapy is not available, autologous HCT is acceptable if not previously performed; if autologous HCT was previously performed, proceed to BiTE or other antibody-based treatment.

¶ Choice of BiTE (eg, glofitamab, epcoritamab) or other antibody-based therapy (eg, tafasitamab, polatuzumab, loncastuximab) is based on availability and clinician/institutional experience; autologous HCT is acceptable if not previously performed.

Graphic 142190 Version 1.0

خرید پکیج

Diffuse large B cell lymphoma: Management of second or later relapse in medically-fit patients